 Celldex Therapeutics Inc NASDAQ: CLDX got a boost Friday with a data readout from Phase 1b trial of CDX-0159 in patients with antihistamine refractory cold urticaria and symptomatic dermographism. The company said that among 19 patients who received a full dose of the antibody, 18 achieved a complete response, and the 19th saw a partial response. 